Zdravljenje trajne KOPB Akutno poslabšanje KOPB

Size: px
Start display at page:

Download "Zdravljenje trajne KOPB Akutno poslabšanje KOPB"

Transcription

1 Prof. dr.stanislav Šuškovič Univerzitetna klinika za pljučne bolezni in alergijo Bolnišnica Golnik 4204 Golnik Zdravljenje trajne KOPB Akutno poslabšanje KOPB Golnik,

2 ZDRAVLJENJE KOPB VZDRŽEVALNO ZDRAVLJENJE ZDRAVLJENJE POSLABŠANJA

3 POSPEŠENI UPAD PLJUČNE FUNKCIJE PRI KOPB učinek opustitve kajenja FEV 1 (% of value at age 25) KOPB invalidnost smrt zdravi Starost v letih stop pri 45 stop pri 65 Adapted from: Fletcher et al, Br Med J 1977.

4 STOPNJA KOPB Blaga FEV 1 /FVC < 70%, FEV 1 >= 80% Zmerna FEV 1 /FVC < 70%, 50%=<FEV 1 < 80% Težka FEV 1 /FVC < 70%, 30%=<FEV 1 < 50% Zelo težka FEV 1 /FVC < 70%, FEV 1 =< 30% ali FEV 1 <50% in kronična repiracijska insuficienca

5 Predpis zdravil po stopnjah KOPB

6 Trajno zdravljenje KOPB z zdravili PRICIP:DODAJANJE Kratkodelujoči bronhodilatator Eden ali več dolgodelujočih bronhodilatatorjev Inhalacijski glukokortikoid Trajno kisik

7 DISPNEJA JE OSREDNJI PROBLEM BOLNIKOV S KOPB UPAD TELESNE KONDICIJE DISPNEJA TELESNA NEAKTIVNOST KAJENJE DEPRESIJA DRUŽBENA IZOLACIJA

8 FEV1 ne korelira z dispnejo ali kakovostjo življenja Dispneja vs FEV1 SGRQ vs FEV1 Kreisman et al,chest1989 PW Jones, THORAX 2001

9 FEV1 ne korelira s telesno zmogljivostjo Cooper BC, Am J Med 2006

10 Hiperinflacija je osrednji patofiziološki pojav pri KOPB

11 Hiperinflacija korelira z dnevno telesno aktivnostjo Garcia-Rio F, AJRCCM 2009

12 KOPB zmanjšana elastičnost pljuč periferna obstrukcija statična ali dinamična hiperinflacija povečano dihalno delo bronhodilatatorji zmanjšujejo hiperiflacijo dispneja

13 salmeterol formoterol indakaterol + tiotropij inhalacijski glukokortikoidi? Zmanjšanje hiperiflacije Olajšanje dispneje

14 KATERO ORODJE ZA OCENO TEŽAVNOSTI KOPB JE NA VOLJO V SLOVENIJI?

15 SGRQ vs. CAT N=229 R=0.80 p<

16

17

18

19 Raziskava TORCH Pogostnost obolevnosti za pljučnico placebo salmeterol flutikazon SFC Pljučnica% * 19.6* Inhalacijski glukokortikoidi povečujejo tveganje za pljučnico

20 Inhaled Corticosteroids and the Risks of Diabetes Onset and Progression Suissa S,Kezouh A,Ernst P Am J Med The cohort included 388,584 patients; of whom 30,167 had diabetes onset during 5.5 years of follow-up (incidence rate 14.2/1000/year); and 2099 subsequently progressed from oral hypoglycemic treatment to insulin (incidence rate 19.8/1000/year). Current use of inhaled corticosteroids was associated with a 34% increase in the rate of diabetes (rate ratio [RR] 1.34; 95% confidence interval [CI], ) and in the rate of diabetes progression (RR 1.34; 95% CI, ). The risk increases were greatest with the highest inhaled corticosteroid doses; equivalent to fluticasone 1000 μg per day or more (RR 1.64; 95% CI, and RR 1.54; 95% CI, ; respectively).

21 NEFARMAKOLOŠKI NAČINI ZDRAVLJENJA KOPB Opustitev kajenja Respiratorna rehabilitacija Ustrezna prehrana Življenski slog

22 Poslabšanje KOPB

23 Simptomi pkopb Poslabšanje kronične obstruktivne Pojačana dispneja Pojačan bolezni kašelj (pkopb) Povečana količina ali gnojnost sputuma Definicija Nagla sprememba v izraženosti Simptom zgornjih dihal (bolečine v grlu, prehlad ) Akutni dispneje, rinitiskašlja in/ali sputuma ter Pojačano drugih simptomov, piskanje ki presega za Stiskanje bolnika v običajno prsnem košu vsakodnevno Zmanjšana variabilnost telesna in zmogljivost ki utegne narekovati Retenca spremembo tekočin zdravljenja Utrujenost Zmedenost

24 Vnetje bronhijev v pkopb pkopb je vselej nasledek povečanega vnetja bronhijev.

25 Etiologija pkopb Bakterijska okužba. Stretococcus pneumonie, Hemophilus influenzae in Moraxella catharrhalis. Virusna okužba rinovirusi, metapnevmovirusi? Bakterijsko-virusna okužba. pomemben delež APKOPB se odvija s kombinirano virusno in bakterijsko okužbo.

26 Simptomi pkopb so podaljšani dispneja rinitis

27 salmeterol formoterol, indakaterol tiotropij inhalacijski glukokortikoidi roflumilast teofilin preprečevanje poslabšanj KOPB Cepljenje proti gripi Respiratorna rehabilitacija

28 ALI Z BRONHODILATATORJI PREPREČUJEMO POSLABŠANJA ASTME IN KOPB? ASTMA NE KOPB DA za 25%

29 Zavzetost za zdravljenje, hospitalizacije in umrljivost bolnikov s KOPB Nezavzeti <=80% Zavzeti >80% Thorax 2009 e-pub

30 Zdravljenje pkopb Bronhodilatatorji 1. V pršilniku preko velikega nastavka (salbutamol ali fenoterol) + ipratropij do 1-6 vdihov/uro 2. nadaljujemo tiotropij na 24 ur + (salmeterol ali formoterol) na 12 ur

31 Cochrane Database Syst Rev. 2003;(2):CD Methylxanthines for exacerbations of chronic obstructive pulmonary disease. Barr RG, Rowe BH,Camargo CA. Pri poslabšanju KOPB ne predpisujemo metilksantinov (aminofilina)

32 Ambulantno antibiotično zdravljenje pkopb le z enostavnimi antibiotiki ni dokazil o prednosti kakega izmed naštetih antibiotikov prvega reda GOLD 2007

33 Glukokortikoidi skrajšajo trajanje in omilijo težo pkopb zmanjšajo možnost zgodnjega ponovnega poslabšanja KOPB GOLD 2007

34 Glukokortikoidi Običajni odmerek: mg metilprednizolona zjutraj 7-10 dni ambulantno predpišemo glukokortikoid le pri bolnikih s predhodnim bazičnim FEV1<50% norme (težka ali zelo težka KOPB po klasifikaciji GOLD) GOLD 2007

35 KOMORBIDNOSTI PRI KOPB 50% bolnikov s KOPB ima vsaj eno komorbidnost DEPRESIJA SLADKORNA BOLEZEN HIPERLIPIDEMIJA OSTEOPOROZA RAK PLJUČ MOTNJE DIHANJA V SPANJU SRČNO POPUŠČANJE

Treatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark

Treatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting

More information

Turning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital

Turning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe

More information

prim. asist. dr. Davorina Petek, dr. med. Katedra za družinsko medicino Poljanski nasip 58, Ljubljana

prim. asist. dr. Davorina Petek, dr. med. Katedra za družinsko medicino Poljanski nasip 58, Ljubljana prim. asist. dr. Davorina Petek, dr. med. Katedra za družinsko medicino Poljanski nasip 58, Ljubljana Model predvideva 6 med seboj povezanih področij Organizacija zdravstvene oskrbe Procedura obravnave

More information

Choosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital

Choosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies

More information

Controversies in Clinical Trials

Controversies in Clinical Trials Controversies in Clinical Trials Christopher B Cooper, MD Professor of Medicine and Physiology David Geffen School of Medicine Medical Director, UCLA COPD Center Methodological issues discussed Pitfalls

More information

Model based longitudinal metaanalysis of FEV1 in COPD trials A tool for efficacy benchmarking

Model based longitudinal metaanalysis of FEV1 in COPD trials A tool for efficacy benchmarking Model based longitudinal metaanalysis of FEV1 in COPD trials A tool for efficacy benchmarking Julia Korell (1), Steven W. Martin (2), Mats O. Karlsson (1), Jakob Ribbing (1,3) (1) Uppsala University, Sweden

More information

รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น

รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines

More information

Priporočila za zdravljenje primarne imunske trombocitopenije. Barbara Skopec

Priporočila za zdravljenje primarne imunske trombocitopenije. Barbara Skopec Priporočila za zdravljenje primarne imunske trombocitopenije Barbara Skopec ITP = Idiopatična trombocitopenična purpura ITP = primarna imunska trombocitopenija Rodeghiero F, et al. Blood 2009;113:2386

More information

The Relationship among COPD Severity, Inhaled Corticosteroid Use, and the Risk of Pneumonia.

The Relationship among COPD Severity, Inhaled Corticosteroid Use, and the Risk of Pneumonia. The Relationship among COPD Severity, Inhaled Corticosteroid Use, and the Risk of Pneumonia. Rennard, Stephen I; Sin, Donald D; Tashkin, Donald P; Calverley, Peter M; Radner, Finn Published in: Annals

More information

Analiza preživetja. Izbrana poglavja iz biomedicinske informatike 2011/2012, LBM2. Asist. dr. Igor Locatelli, mag. farm.

Analiza preživetja. Izbrana poglavja iz biomedicinske informatike 2011/2012, LBM2. Asist. dr. Igor Locatelli, mag. farm. Analiza preživetja Izbrana poglavja iz biomedicinske informatike 2011/2012, LBM2 Asist. dr. Igor Locatelli, mag. farm. Ljubljana, 16. 12. 2011 Analiza preživetja Survival analysis Proučevanje (modeliranje)

More information

DISPNEJA, SLABOST, DELIRIJ

DISPNEJA, SLABOST, DELIRIJ Lajšanje telesnih simptomov: DISPNEJA, SLABOST, DELIRIJ Urška Lunder Univerzitetna klinika za pljučne bolezni in alergijo Golnik Ljubljana, 1. februar 2010 Najbolj učinkovit u je celosten interdisciplinarni

More information

Disease progression in COPD:

Disease progression in COPD: Disease progression in COPD: What is it? How should it be measured? Can it be modified? Professor Paul Jones MD, PhD, FERS Emeritus Professor of Respiratory Medicine; St George s, University of London

More information

Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015

Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong

More information

aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.

aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and

More information

Disclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:

Disclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to: Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict

More information

Pharmacotherapy for COPD

Pharmacotherapy for COPD 10/3/2017 Topics to be covered Pharmacotherapy for chronic treatment Pharmacotherapy for COPD Dr. W C Yu 3rd September 2017 Commonly used drugs Guidelines for their use Inhaled corticosteroids (ICS) in

More information

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH

More information

Epidemiology of COPD Prof. David M. Mannino, M.D.

Epidemiology of COPD Prof. David M. Mannino, M.D. Epidemiology of COPD David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health College of Public Health University of Kentucky 1 Outline Definitions Severity Progression

More information

Protokol kronična obstruktivna pljučna bolezen (KOPB) Protokol vodenja kroničnega bolnika na primarnem nivoju in ukrepanje ob zapletih/poslabšanjih

Protokol kronična obstruktivna pljučna bolezen (KOPB) Protokol vodenja kroničnega bolnika na primarnem nivoju in ukrepanje ob zapletih/poslabšanjih Protokol kronična obstruktivna pljučna bolezen (KOPB) Protokol vodenja kroničnega bolnika na primarnem nivoju in ukrepanje ob zapletih/poslabšanjih Tonka Poplas Susič, Vlasta Vodopivec Jamšek, Mitja Košnik,

More information

Blood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial. Online Data Supplement

Blood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial. Online Data Supplement Blood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial Nicolas Roche, Kenneth R. Chapman, Claus F. Vogelmeier, Felix JF Herth, Chau Thach, Robert Fogel, Petter Olsson,

More information

Aclidinium bromide/formoterol Endpoint category. RR Endpoint. [95% CI 2 ] Study. with event

Aclidinium bromide/formoterol Endpoint category. RR Endpoint. [95% CI 2 ] Study. with event Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in

More information

Shaping a Dynamic Future in Respiratory Practice. #DFResp

Shaping a Dynamic Future in Respiratory Practice. #DFResp Shaping a Dynamic Future in Respiratory Practice #DFResp www.dynamicfuture.co.uk Inhaled Therapy in COPD: Past, Present and Future Richard Russell Chest Physician West Hampshire Integrated Respiratory

More information

COPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms

COPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and

More information

COPD: A Renewed Focus. Disclosures

COPD: A Renewed Focus. Disclosures COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss

More information

At-A-Glance Outpatient Management Reference for Chronic Obstructive Pulmonary Disease (COPD)

At-A-Glance Outpatient Management Reference for Chronic Obstructive Pulmonary Disease (COPD) At-A-Glance Outpatient Management Reference f Chronic Obstructive Pulmonary Disease (COPD) BASED ON THE GLOBAL STRATEGY FOR DIAGNOSIS, MANAGEMENT AND PREVENTION OF COPD GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE

More information

Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD)

Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) Zahava Picado, PharmD PGY1 Pharmacy Practice Resident Central Texas Veterans Healthcare System Temple, TX October

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 15 December 2010

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 15 December 2010 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 December 2010 HIROBRIZ BREEZHALER 150 micrograms, inhalation powder, hard capsules B/10 with inhaler (CIP code:

More information

II: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical

II: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%

More information

Surveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.

Surveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved. Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights

More information

Debating the use of inhaled corticosteroids in the treatment of COPD. COPD Epidemiology. A quick patient case. Risk Factors for COPD 1,2

Debating the use of inhaled corticosteroids in the treatment of COPD. COPD Epidemiology. A quick patient case. Risk Factors for COPD 1,2 Debating the use of inhaled corticosteroids in the treatment of COPD Suzanne G. Bollmeier Pharm.D., BCPS, AE-C Associate Professor, St. Louis College of Pharmacy ACPE Guidelines on Non- Commercialism o

More information

} ZDRUŽENJE PNEVMOLOGOV SLOVENIJE. Zbornik sestanka: Simpozij o kašlju

} ZDRUŽENJE PNEVMOLOGOV SLOVENIJE. Zbornik sestanka: Simpozij o kašlju } ZDRUŽENJE PNEVMOLOGOV SLOVENIJE Zbornik sestanka: Simpozij o kašlju Ljubljana, Medicinska fakulteta 10. maj 2008 Izdajatelj Združenje pnevmologov Slovenije Urednik zbornika Nadja Triller Matjaž Turel

More information

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease Chronic Obstructive Pulmonary Disease Catherine Whittaker (BPharm, MRPharmS) Abstract Chronic Obstructive Pulmonary Disease affects millions of people, has a major impact on quality of life and has become

More information

Research Review. Salmeterol/fluticasone propionate (Seretide ) in COPD. Extended listing for salmeterol/fluticasone propionate in COPD

Research Review. Salmeterol/fluticasone propionate (Seretide ) in COPD. Extended listing for salmeterol/fluticasone propionate in COPD Research Review Salmeterol/fluticasone propionate (Seretide ) in COPD Extended listing for salmeterol/fluticasone propionate in COPD In New Zealand, salmeterol/fluticasone propionate (SFC) (Seretide )

More information

Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC

Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC I have no financial disclosures Definition COPD is a preventable and treatable disease

More information

UPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

UPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE UPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE Radhika Shah, MD Erlanger Health System University of Tennessee College of Medicine Chattanooga Respiratory, Critical Care, and Sleep medicine No disclosures

More information

COPD The New Epidemic. Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre

COPD The New Epidemic. Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre COPD The New Epidemic Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre Conflict Disclosure Information Speaker: Dr. Peter Lin Title of Talk: COPD The New Epidemic Financial

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 25 May 2011

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 25 May 2011 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 25 May 2011 Examination of the file for the proprietary medicinal product included for a period of 5 years by the

More information

Inhaled corticosteroids versus long-acting beta 2 -agonists for chronic obstructive pulmonary disease (Review)

Inhaled corticosteroids versus long-acting beta 2 -agonists for chronic obstructive pulmonary disease (Review) Inhaled corticosteroids versus long-acting beta 2 -agonists for chronic obstructive pulmonary disease (Review) Spencer S, Evans DJ, Karner C, Cates CJ This is a reprint of a Cochrane review, prepared and

More information

Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD

Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD Send Orders of Reprints at bspsaif@emirates.net.ae 150 The Open Respiratory Medicine Journal, 2012, 6, 150-154 Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD Charlotte Suppli

More information

COPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health

COPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or

More information

11/27/18. Challenges in Pulmonary and Critical Care: COPD So Much is New! Faculty. Disclosures

11/27/18. Challenges in Pulmonary and Critical Care: COPD So Much is New! Faculty. Disclosures Challenges in Pulmonary and Critical Care: 2018 COPD So Much is New! 1 Faculty Anas Hadeh, MD, FCCP Director, Pulmonary and Critical Care Medicine Fellowship Program Affiliate Assistant Professor of Clinical

More information

Dr Stephen Child. General Physician Auckland. 14:20-14:40 Secondary Care Perspective

Dr Stephen Child. General Physician Auckland. 14:20-14:40 Secondary Care Perspective Dr Stephen Child General Physician Auckland 14:20-14:40 Secondary Care Perspective Wheeze Witchery Stephen Child MD, FRACP, FRCPC General Physician Respiratory Interest Director of Clinical Training Auckland

More information

Three s Company - The role of triple therapy in chronic obstructive pulmonary

Three s Company - The role of triple therapy in chronic obstructive pulmonary Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov

More information

Optimum COPD Care in 2010 Why Not Now? David E. Taylor, M.D. Pulmonary/Critical Care Ochnser Medical Center

Optimum COPD Care in 2010 Why Not Now? David E. Taylor, M.D. Pulmonary/Critical Care Ochnser Medical Center Optimum COPD Care in 2010 Why Not Now? David E. Taylor, M.D. Pulmonary/Critical Care Ochnser Medical Center dtaylor@ochsner.org Observations from Yesterday EPIC is epidemic No EMR No Way!!! Accountability/Benchmarking

More information

What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university

What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent

More information

COPD is a significant cause of mortality

COPD is a significant cause of mortality RESPIRATORY CLINICAL FOCUS Comparing the range and costs of COPD treatments in primary care Practice nurses should familiarise themselves with the many products available for the management of chronic

More information

Antikoagulantno zdravljenje

Antikoagulantno zdravljenje Antikoagulantno zdravljenje (novosti s kongresa ASH 2010) Irena Umek Bricman Oddelek za interno medicino SB Slovenj Gradec Podčetrtek, 15.04.2010 Trajanje antikoagulantne terapije Priporočila: 8th ACCP

More information

Posebnosti okužb pri otroku. Prof. dr. Milan Čižman, dr. med. Klinika za infekcijske bolezni in vročinska stanja, UKCL

Posebnosti okužb pri otroku. Prof. dr. Milan Čižman, dr. med. Klinika za infekcijske bolezni in vročinska stanja, UKCL Posebnosti okužb pri otroku Prof. dr. Milan Čižman, dr. med. Klinika za infekcijske bolezni in vročinska stanja, UKCL Značilnosti okužb pri otrocih Pogoste so okužbe pri otrocih brez pridobljene imunosti

More information

What is COPD? COPD Pharmacotherapy. COPD Mortality Is Increasing

What is COPD? COPD Pharmacotherapy. COPD Mortality Is Increasing COPD Pharmacotherapy Chronic Bronchitis What is COPD? 75% 17.5% Emphysema Laura C. Feemster, MD, MS Assistant Professor University of Washington Division of Pulmonary & Critical Care April 23,2015 COPD

More information

TREAMENT OF RECURRENT VIRUS-INDUCED WHEEZING IN YOUNG CHILDREN. Dr Lại Lê Hưng Respiratory Department

TREAMENT OF RECURRENT VIRUS-INDUCED WHEEZING IN YOUNG CHILDREN. Dr Lại Lê Hưng Respiratory Department TREAMENT OF RECURRENT VIRUS-INDUCED WHEEZING IN YOUNG CHILDREN Dr Lại Lê Hưng Respiratory Department Literature review current through: Feb 2013. This topic last updated: Aug 14, 2012 INTRODUCTION Wheezing

More information

Kirthi Gunasekera MD Respiratory Physician National Hospital of Sri Lanka Colombo,

Kirthi Gunasekera MD Respiratory Physician National Hospital of Sri Lanka Colombo, Kirthi Gunasekera MD Respiratory Physician National Hospital of Sri Lanka Colombo, BRONCHODILATORS: Beta Adrenoreceptor Agonists Actions Adrenoreceptor agonists have many of the same actions as epinephrine/adrenaline,

More information

Okužbe in posebnosti rabe antibiotikov pri starostnikih. Tatjana Lejko-Zupanc UKC Ljubljana Klinika za infekcijske bolezni in vročinska stanja

Okužbe in posebnosti rabe antibiotikov pri starostnikih. Tatjana Lejko-Zupanc UKC Ljubljana Klinika za infekcijske bolezni in vročinska stanja Okužbe in posebnosti rabe antibiotikov pri starostnikih Tatjana Lejko-Zupanc UKC Ljubljana Klinika za infekcijske bolezni in vročinska stanja Kronološka starost Skupina starejših > 65 let Mlajši starejši

More information

Patient characteristics Intervention Comparison Length of followup

Patient characteristics Intervention Comparison Length of followup ORAL MUCOLYTICS Ref ID: 2511 Bachh AA, Shah NN, Bhargava R et al. Effect oral N- in COPD - A randomised controlled trial. JK Practitioner. 2007; 14(1):12-16. Ref ID: 2511 RCT Single blind; unclear allocation

More information

Inhaled corticosteroids versus long-acting beta 2 -agonists for chronic obstructive pulmonary disease (Review)

Inhaled corticosteroids versus long-acting beta 2 -agonists for chronic obstructive pulmonary disease (Review) Inhaled corticosteroids versus long-acting beta 2 -agonists for chronic obstructive pulmonary disease (Review) Spencer S, Karner C, Cates CJ, Evans DJ This is a reprint of a Cochrane review, prepared and

More information

REDUCE AND PREVENT IS IT EASY?

REDUCE AND PREVENT IS IT EASY? REDUCE AND PREVENT EXACERBATION IN COPD PATIENTS: IS IT EASY? พ.ญ. ณ บผล กา กองพลพรหม สาขาว ชาโรคระบบทางเด นหายใจและเวชบ าบ ดว กฤต ภาคว ชาอาย รศาสตร คณะแพทยศาสตร จ ฬาลงกรณ มหาว ทยาล ย How COPD Affects

More information

MODUL: ASTMA; KOPB; ALERGIJSKI RINITIS PROGRAM ZA MEDICINSKE SESTRE V REFERENČNIH AMBULANTAH. Golnik, 5., 6., 7. in 8. april 2016

MODUL: ASTMA; KOPB; ALERGIJSKI RINITIS PROGRAM ZA MEDICINSKE SESTRE V REFERENČNIH AMBULANTAH. Golnik, 5., 6., 7. in 8. april 2016 14 UNIVERZITETNA KLINIKA ZA PLJUČNE BOLEZNI IN ALERGIJO GOLNIK MODUL: ASTMA; KOPB; ALERGIJSKI RINITIS PROGRAM ZA MEDICINSKE SESTRE V REFERENČNIH AMBULANTAH Golnik, 5., 6., 7. in 8. april 2016 MODUL: ASTMA;

More information

The beneficial effects of ICS in COPD

The beneficial effects of ICS in COPD BIOLOGY AND HEALTH Journal website: www.biologyandhealth.com Narrative review The beneficial effects of ICS in COPD Stacha Reumers Stacha Reumers I6111431 Maastricht University Faculty of Health, Medicine

More information

A comparison of global questions versus health status questionnaires as measures of the severity and impact of asthma

A comparison of global questions versus health status questionnaires as measures of the severity and impact of asthma Eur Respir J 1999; 1: 591±596 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 1999 European Respiratory Journal ISSN 93-1936 A comparison of global questions versus health status questionnaires

More information

Drug Class Monograph

Drug Class Monograph Drug Class Monograph Class: Inhaled Corticosteroids Drugs: Aerospan (flunisolide), Advair Diskus, Advair HFA (fluticasone/salmeterol), Alvesco (ciclesonide), Arnuity Ellipta (fluticasone furoate), Asmanex

More information

Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited

Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited Eur Respir J 28; 32: 17 24 DOI: 1.1183/931936.16157 CopyrightßERS Journals Ltd 28 PERSPECTIVE Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited O.N. Keene*, P.M.A. Calverley

More information

Drug Monograph. Brand Name: Arcapta Neohaler. Generic Name: Indacaterol. Manufacturer¹,²: Novartis

Drug Monograph. Brand Name: Arcapta Neohaler. Generic Name: Indacaterol. Manufacturer¹,²: Novartis Drug Monograph Brand Name: Arcapta Neohaler Generic Name: Indacaterol Manufacturer¹,²: Novartis Drug Class¹,²,³, : Beta2-Adrenergic Agonist, Long-Acting Uses: Labeled Uses¹,²,³, : Used for long-term maintenance

More information

Searching for Targets to Control Asthma

Searching for Targets to Control Asthma Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important

More information

Chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease Chronic obstructive pulmonary disease Abstract Whittaker C, BPharm, MRPharmS Amayeza Info Centre Chronic obstructive pulmonary disease affects millions of people, has a major impact on quality of life

More information

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma

More information

Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore $

Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore $ Respiratory Medicine (2006) 100, 2190 2196 Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore $ Kang-Hoe

More information

Potential risks of ICS use

Potential risks of ICS use Potential risks of ICS use Randomised controlled trial Observational study Systematic review Pneumonia Tuberculosis Bone fracture Skin thinning/easy bruising Cataract Diabetes No effect on fracture risk

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Supplementary Medications during asthma attack. Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus

Supplementary Medications during asthma attack. Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus Supplementary Medications during asthma attack Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus Conflicts of Interest None Definition of Asthma Airway narrowing that is

More information

Shaping a Dynamic Future in Respiratory Practice. #DFResp

Shaping a Dynamic Future in Respiratory Practice. #DFResp Shaping a Dynamic Future in Respiratory Practice #DFResp www.dynamicfuture.co.uk Inhaled Therapy in COPD: Past, Present and Future Richard Russell Chest Physician West Hampshire Integrated Respiratory

More information

Roflumilast (Daxas) for chronic obstructive pulmonary disease

Roflumilast (Daxas) for chronic obstructive pulmonary disease Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended

More information

Chronic obstructive pulmonary disease (COPD) is characterized

Chronic obstructive pulmonary disease (COPD) is characterized DANIEL E. HILLEMAN, PharmD ABSTRACT OBJECTIVE: To review the role of long-acting bronchodilators in the treatment of chronic obstructive pulmonary disease (COPD), including the importance of treatment

More information

Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018

Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018 Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

Changing Epidemiology: Quick Facts 9/28/2018. During the year New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits?

Changing Epidemiology: Quick Facts 9/28/2018. During the year New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits? New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits? Conflict of Interest Statement 2018 Speakers Bureau Astra Zeneca Boehringer Ingelheim Genentech Sunovion Ron Balkissoon MD DIH

More information

Combination inhaled steroid and long-acting beta -agonist in

Combination inhaled steroid and long-acting beta -agonist in Combination inhaled steroid and long-acting beta 2 -agonist in addition to tiotropium versus tiotropium or combination alone for chronic Karner C, Cates CJ This is a reprint of a Cochrane review, prepared

More information

Fixed combination therapies in COPD effect on quality of life

Fixed combination therapies in COPD effect on quality of life REVIEW Fixed combination therapies in COPD effect on quality of life Beatrix Groneberg-Kloft 1,2 Axel Fischer 2 Tobias Welte 1 1 Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany;

More information

This is the publisher s version. This version is defined in the NISO recommended practice RP

This is the publisher s version. This version is defined in the NISO recommended practice RP Journal Article Version This is the publisher s version. This version is defined in the NISO recommended practice RP-8-2008 http://www.niso.org/publications/rp/ Suggested Reference Chong, J., Karner, C.,

More information

GINKGO BILOBA IN MISELNE SPOSOBNOSTI. Avtorji: Jelena Raković, Božica Ljušanin Grbavac 18. modularna skupina April 2015

GINKGO BILOBA IN MISELNE SPOSOBNOSTI. Avtorji: Jelena Raković, Božica Ljušanin Grbavac 18. modularna skupina April 2015 GINKGO BILOBA IN MISELNE SPOSOBNOSTI Avtorji: Jelena Raković, Božica Ljušanin Grbavac 18. modularna skupina April 2015 KLINIČNO VPRAŠANJE Ali uporaba standardiziranih pripravkov Ginkgo bilobe izboljšuje

More information

Zdravljenje pridobljene hemofilije. Irena Preložnik Zupan

Zdravljenje pridobljene hemofilije. Irena Preložnik Zupan Zdravljenje pridobljene hemofilije Irena Preložnik Zupan CILJI 1. Definicija, klinična slika, diagnoza 2. Zdravljenje zdravljenje akutnih krvavitev odstranjevanje inhibitorjev Pridobljeni inhibitorji koagulacije

More information

Utilization of LABAs versus SABAs in Albanian Insured Outpatients with COPD during

Utilization of LABAs versus SABAs in Albanian Insured Outpatients with COPD during Utilization of LABAs versus SABAs in Albanian Insured Outpatients with COPD during 2008-2012 Doi:10.5901/mjss.2013.v4n9p573 Abstract Alida Sina PhD Student, Health Insurance Institute, Tirana, Albania

More information

Decramer 2014 a &b [21]

Decramer 2014 a &b [21] Buhl 2015 [19] Celli 2014 [20] Decramer 2014 a &b [21] D Urzo 2014 [22] Maleki-Yazdi 2014 [23] Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease; 40 years of age or older; Relatively

More information

Aclidinium bromide/ formoterol Benefit assessment according to 35a Social Code Book V 1

Aclidinium bromide/ formoterol Benefit assessment according to 35a Social Code Book V 1 IQWiG Reports Commission No. A15-06 Aclidinium bromide/ formoterol Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Aclidiniumbromid/Formoterol

More information

Class Update: Asthma / COPD Medications

Class Update: Asthma / COPD Medications Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Preventing clinically important deterioration with single-inhaler triple therapy in COPD

Preventing clinically important deterioration with single-inhaler triple therapy in COPD ORIGINAL ARTICLE COPD Preventing clinically important deterioration with single-inhaler triple therapy in COPD Ian Naya 1, Chris Compton 1, Afisi S. Ismaila 2,3, Ruby Birk 4, Noushin Brealey 4, Maggie

More information

The impacts of cognitive impairment on acute exacerbations of chronic obstructive pulmonary disease

The impacts of cognitive impairment on acute exacerbations of chronic obstructive pulmonary disease The impacts of cognitive impairment on acute exacerbations of chronic obstructive pulmonary disease Dr. Lo Iek Long Department of Respiratory Medicine C.H.C.S.J. Chronic Obstructive Pulmonary Disease (COPD)

More information

Re-Submission. roflumilast, 500 microgram, film-coated tablet (Daxas ) SMC No 635/10 AstraZeneca UK Ltd. Published 11 September

Re-Submission. roflumilast, 500 microgram, film-coated tablet (Daxas ) SMC No 635/10 AstraZeneca UK Ltd. Published 11 September Re-Submission roflumilast, 500 microgram, film-coated tablet (Daxas ) SMC No 635/10 AstraZeneca UK Ltd 4 August 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product

More information

Defining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist

Defining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease

More information

Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives : Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives : Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD

INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD ORIGINAL ARTICLE COPD INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD Andrea Rossi 1, Thys van der Molen 2, Ricardo del Olmo 3, Alberto Papi 4, Luis Wehbe

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #52 (NQF 0102): Chronic Obstructive Pulmonary Disease (COPD): Long-Acting Inhaled Bronchodilator Therapy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL

More information

Bronchiectasis Domiciliary treatment. Prof. Adam Hill Royal Infirmary and University of Edinburgh

Bronchiectasis Domiciliary treatment. Prof. Adam Hill Royal Infirmary and University of Edinburgh Bronchiectasis Domiciliary treatment Prof. Adam Hill Royal Infirmary and University of Edinburgh Plan of talk Background of bronchiectasis Who requires IV antibiotics Domiciliary treatment Results to date.

More information

Disclosures. Update on COPD & Asthma. Update on the Management of COPD. No Pharma Disclosures. NHLBI - Asthma Clinical Research Network

Disclosures. Update on COPD & Asthma. Update on the Management of COPD. No Pharma Disclosures. NHLBI - Asthma Clinical Research Network Update on COPD & Asthma Michael C. Peters, M.D. MAS Division of Pulmonary & Critical Care Medicine Cardiovascular Research Institute University of California San Francisco UCSF Primary Care Medicine San

More information

glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd.

glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd. glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd. 07 December 2012 The Scottish Medicines Consortium (SMC) has completed

More information

roflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd

roflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd roflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd 06 August 2010 (Issued 10 September 2010) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

Presenter Disclosure Information

Presenter Disclosure Information 12:45 1:3 pm Improving Outcomes in COPD SPEAKER Michael Campos, MD Presenter Disclosure Information The following relationships exist related to this presentation: Michael Campos, MD: No financial relationships

More information

NANČA ČEBRON LIPOVEC METABOLIČNI PROFILI BOLNIKOV S KRONIČNO OBSTRUKTIVNO PLJUČNO BOLEZNIJO PRED IN PO REHABILITACIJI DOKTORSKA DISERTACIJA

NANČA ČEBRON LIPOVEC METABOLIČNI PROFILI BOLNIKOV S KRONIČNO OBSTRUKTIVNO PLJUČNO BOLEZNIJO PRED IN PO REHABILITACIJI DOKTORSKA DISERTACIJA NANČA ČEBRON LIPOVEC METABOLIČNI PROFILI BOLNIKOV S KRONIČNO OBSTRUKTIVNO PLJUČNO BOLEZNIJO PRED IN PO REHABILITACIJI DOKTORSKA DISERTACIJA LJUBLJANA, 2016 I NANČA ČEBRON LIPOVEC METABOLIC PROFILES OF

More information

Cost-Effectiveness of Therapy with Combinations of Long-Acting Bronchodilators and Inhaled Steroids for Treatment of COPD

Cost-Effectiveness of Therapy with Combinations of Long-Acting Bronchodilators and Inhaled Steroids for Treatment of COPD Collaboration for Outcomes Research and Evaluation University of British Columbia Cost-Effectiveness of Therapy with Combinations of Long-Acting Bronchodilators and Inhaled Steroids for Treatment of COPD

More information

umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline

umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline 07 November 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product

More information

Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Secondary Outcome/Efficacy Variable(s): Statistical Methods:

Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Secondary Outcome/Efficacy Variable(s): Statistical Methods: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information